Black Rock Inc. Cullinan Oncology, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,550,207 shares of CGEM stock, worth $57.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,550,207
Previous 2,428,993
46.16%
Holding current value
$57.6 Million
Previous $41.4 Million
49.59%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CGEM
# of Institutions
141Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$124 Million21.42% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$93.3 Million3.07% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$55.4 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$53.2 Million1.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$46.6 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $740M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...